デングワクチン市場：ワクチンタイプ別、エンドユーザー別、年齢層別、ワクチン開発段階別、流通チャネル別、投与経路別、技術別、患者タイプ別-2025～2030年世界予測

デングワクチン市場は、2023年に13億8,000万米ドルと評価され、2024年には15億3,000万米ドルに達すると予測され、CAGR 11.79%で成長し、2030年には30億2,000万米ドルに達すると予測されています。

世界のデングワクチン市場は、蚊が媒介する熱帯病であり、毎年数100万人が罹患するデング熱対策において重要な役割を果たすことが認識されています。デング熱の罹患率と死亡率を減少させるという公衆衛生上の緊急課題に対処するため、予防的と治療的ソリューションの両方が対象となります。デングワクチンの必要性は、気候変動、都市化、旅行の増加により、熱帯・亜熱帯地域でこの病気がますます流行していることからも明らかです。用途としては、主に流行地域の青少年や成人を対象とした予防接種プログラムが挙げられます。最終用途には、病院、クリニック、公衆衛生センターが含まれ、旅行センターや観光の拠点に拡大する可能性もあります。

市場の成長には、蚊が媒介する病気に対する意識の高まり、予防接種に対する政府の取り組み、弱毒生ワクチンや組み換えワクチンなどのワクチン技術の進歩など、いくつかの要因が影響しています。東南アジア、ラテンアメリカ、アフリカの新興市場全体の需要を刺激し、ワクチンの適用範囲を世界的に拡大することにビジネス機会があります。様々なデングウイルス血清型を標的とした多価ワクチンの開発は、コンプライアンスやアクセシビリティを向上させる経口や経皮などの新規デリバリーシステムの探求と同様に、大きな機会を記載しています。

課題としては、特に多様な集団や血清型における安全性と有効性に関する規制上のハードルがあり、これが承認プロセスを阻害する可能性があります。さらに、ワクチンの流通やコールドチェーンの維持における物流の問題が現実的な障壁となっています。ワクチンは比較的高価であるため、低所得地域ではアクセスが制限される可能性があり、スケーラブルな生産と価格戦略が必要となります。

革新的な研究対象としては、mRNAやベクターベースの技術といった最先端のプラットフォームを活用し、より広い血清型をカバーし、免疫持続期間の長いワクチンを開発することが挙げられます。さらに、蚊の駆除対策との相乗効果を模索し、より広範な保健戦略にワクチンを組み込むことで、より包括的な疾病管理が可能になります。市場の性質はダイナミックであり、技術の進歩や疫学的パターンの変化によって左右されるため、インパクトのある健康成果を達成するためには、継続的な調査と部門を超えた協力が必要であることが強調されています。

市場力学：急速に進化するデングワクチン市場の主要市場洞察を公開

デングワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のデング熱患者の増加により、感染地域でのワクチン需要が増加
  • デング熱の発生を抑制・予防するための政府・非政府組織によるイニシアチブの高まり
  • より効果的なデング熱ワクチンの開発を促進するバイオテクノロジーの急速な進歩
  • デング熱ワクチン接種の重要性に関する国民の認識と教育キャンペーンの高まり
• 市場抑制要因
  • 高い研究開発費と臨床試験費用
• 市場機会
  • デング熱ワクチンの認知度向上とリスク集団への普及を目的としたマーケティング戦略の市場開拓
  • 官民パートナーシップを確立し、調査と配布に資金を提供し加速させる
  • デジタルヘルスツールの活用による、ワクチン接種後の転帰の監視・管理による継続的改善
• 市場課題
  • ワクチン配送における物流の問題とワクチン接種のためらい

ポーターの5つの力：デングワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：デングワクチン市場における外部からの影響の把握

外部マクロ環境要因は、デングワクチン市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析デングワクチン市場における競合情勢の把握

デングワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックスデングワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、デングワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨デングワクチン市場における成功への道筋を描く

デングワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • デング熱の世界の発生率増加により、感染地域でのワクチン需要が増加
    • デング熱の流行を抑制し予防するための政府と非政府組織の取り組みが拡大
    • バイオテクノロジーの急速な進歩により、より効果的なデング熱ワクチンの開発が促進される
    • デング熱ワクチン接種の重要性に関する国民の意識と教育キャンペーンの高まり
  • 抑制要因
    • 研究開発費と臨床試験費の高騰
  • 機会
    • リスクのある人々の間でデング熱ワクチンの認知度と採用を高めるための対象マーケティング戦略の開発
    • 調査と配布に資金を提供し加速するための官民パートナーシップの構築
    • デジタルヘルスツールを活用してワクチン接種後の成果を監視・管理し、継続的な改善を図る
  • 課題
    • ワクチン配送における物流上の問題とワクチン接種への躊躇
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 デングワクチン市場：ワクチンタイプ別

• イントロダクション
• DNAワクチン
• 不活化ワクチン
• 生弱毒化ワクチン
• 組み換えワクチン
• サブユニットワクチン

第7章 デングワクチン市場：エンドユーザー別

• イントロダクション
• クリニック
• 政府と非政府組織
• 病院
• 研究機関

第8章 デングワクチン市場：年齢層別

• イントロダクション
• 青年
• 成人
• 小児

第9章 デングワクチン市場：ワクチン開発段階別

• イントロダクション
• 臨床試験
• フェーズI
• フェーズII
• フェーズIII
• 前臨床

第10章 デングワクチン市場：流通チャネル別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第11章 デングワクチン市場：投与経路別

• イントロダクション
• 注射
• 鼻腔
• 経口

第12章 デングワクチン市場：技術別

• イントロダクション
• 従来型ワクチン
  • ウイルスワクチンの分割
  • 全ウイルスワクチン
• 次世代ワクチン
  • ウイルス様粒子

第13章 デングワクチン市場：患者タイプ別

• イントロダクション
• 症候性

第14章 南北アメリカのデングワクチン市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第15章 アジア太平洋のデングワクチン市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第16章 欧州・中東・アフリカのデングワクチン市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第17章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

LIST OF FIGURES

• FIGURE 1. DENGUE VACCINE MARKET RESEARCH PROCESS
• FIGURE 2. DENGUE VACCINE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
• FIGURE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 25. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 27. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 28. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 29. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 30. DENGUE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 31. DENGUE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DENGUE VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DENGUE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DENGUE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DENGUE VACCINE MARKET DYNAMICS
• TABLE 7. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DENGUE VACCINE MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DENGUE VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DENGUE VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DENGUE VACCINE MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DENGUE VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DENGUE VACCINE MARKET SIZE, BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DENGUE VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DENGUE VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DENGUE VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DENGUE VACCINE MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DENGUE VACCINE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DENGUE VACCINE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DENGUE VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DENGUE VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DENGUE VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DENGUE VACCINE MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL DENGUE VACCINE MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL DENGUE VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL DENGUE VACCINE MARKET SIZE, BY SPLIT VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL DENGUE VACCINE MARKET SIZE, BY WHOLE VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL DENGUE VACCINE MARKET SIZE, BY VIRUS-LIKE PARTICLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL DENGUE VACCINE MARKET SIZE, BY SYMPTOMATIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. CANADA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. CANADA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. CANADA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 80. CANADA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 81. CANADA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. CANADA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. CANADA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. CANADA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 85. CANADA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 86. CANADA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES DENGUE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 130. CHINA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. CHINA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 132. CHINA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 133. CHINA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. CHINA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. CHINA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. CHINA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 137. CHINA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 138. CHINA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. INDIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. INDIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. INDIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 142. INDIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 143. INDIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. INDIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. INDIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. INDIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 147. INDIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 148. INDIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 157. INDONESIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 167. JAPAN DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 177. MALAYSIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 187. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 197. SINGAPORE DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 217. TAIWAN DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 227. THAILAND DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 237. VIETNAM DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA DENGUE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 250. DENMARK DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 251. DENMARK DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 258. DENMARK DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 260. EGYPT DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 261. EGYPT DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 268. EGYPT DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 270. FINLAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 271. FINLAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 278. FINLAND DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 280. FRANCE DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 281. FRANCE DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 288. FRANCE DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 290. GERMANY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 291. GERMANY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 292. GERMANY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 295. GERMANY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 296. GERMANY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 298. GERMANY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 299. GERMANY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 300. ISRAEL DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 301. ISRAEL DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 302. ISRAEL DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 308. ISRAEL DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 309. ISRAEL DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 310. ITALY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 311. ITALY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 312. ITALY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 313. ITALY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 314. ITALY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 315. ITALY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 316. ITALY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 317. ITALY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 318. ITALY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 319. ITALY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 320. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 321. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 322. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 323. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 324. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 325. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 326. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 327. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 328. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 329. NETHERLANDS DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 330. NIGERIA DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 331. NIGERIA DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 332. NIGERIA DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 333. NIGERIA DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 334. NIGERIA DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 335. NIGERIA DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 336. NIGERIA DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 337. NIGERIA DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 338. NIGERIA DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 339. NIGERIA DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 340. NORWAY DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 341. NORWAY DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 342. NORWAY DENGUE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 343. NORWAY DENGUE VACCINE MARKET SIZE, BY VACCINE DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 344. NORWAY DENGUE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 345. NORWAY DENGUE VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 346. NORWAY DENGUE VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 347. NORWAY DENGUE VACCINE MARKET SIZE, BY CONVENTIONAL VACCINES, 2018-2030 (USD MILLION)
• TABLE 348. NORWAY DENGUE VACCINE MARKET SIZE, BY NEXT-GENERATION VACCINES, 2018-2030 (USD MILLION)
• TABLE 349. NORWAY DENGUE VACCINE MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 350. POLAND DENGUE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
• TABLE 351. POLAND DENGUE VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 352.

The Dengue Vaccine Market was valued at USD 1.38 billion in 2023, expected to reach USD 1.53 billion in 2024, and is projected to grow at a CAGR of 11.79%, to USD 3.02 billion by 2030.

The global dengue vaccine market is recognized for its critical role in combating dengue fever, a mosquito-borne tropical disease affecting millions annually. The scope encompasses both prophylactic and therapeutic solutions, addressing the urgent public health need to reduce dengue incidence and mortality. The necessity of the dengue vaccine is underscored by the increasing prevalence of the disease in tropical and subtropical regions, fueled by climate change, urbanization, and increased travel. Applications primarily involve immunization programs targeting adolescents and adults in endemic regions. End-use scope includes hospitals, clinics, and public health centers, with potential expansion into travel centers and tourist hubs.

Market growth is influenced by several factors, including rising awareness about mosquito-borne diseases, government initiatives for immunization, and advancements in vaccine technologies, such as live attenuated vaccines and recombinant vaccines. Opportunities lie in expanding vaccine coverage globally, stimulating demand across emerging markets in Southeast Asia, Latin America, and Africa. Developing multi-valent vaccines targeting various dengue virus serotypes offers a significant opportunity, as does exploring novel delivery systems, such as oral or transdermal routes, which can enhance compliance and accessibility.

Challenges include regulatory hurdles, particularly concerning safety and efficacy across diverse populations and serotypes, which can impede approval processes. Additionally, logistical issues in vaccine distribution and cold chain maintenance pose practical barriers. The relatively high cost of vaccines can limit access in low-income regions, necessitating scalable production and pricing strategies.

Innovative areas for research include developing vaccines with broader serotype coverage and longer immunity duration, utilizing cutting-edge platforms like mRNA and vector-based technologies. Moreover, exploring synergies with mosquito control initiatives and integrating vaccines into broader health strategies could ensure more comprehensive disease management. The nature of the market is dynamic, driven by technological progress and shifting epidemiological patterns, underscoring the need for continuous research and collaboration across sectors to achieve impactful health outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dengue Vaccine Market

The Dengue Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increased global incidence of dengue fever cases leading to higher demand for vaccines in affected regions
  • Growing government and non-governmental organizations' initiatives to control and prevent dengue outbreaks
  • Rapid advancements in biotechnology facilitating the development of more effective dengue vaccines
  • Rising public awareness and education campaigns about the importance of dengue vaccination
• Market Restraints
  • High R&D and clinical trial costs
• Market Opportunities
  • Developing targeted marketing strategies to increase awareness and adoption of dengue vaccines among at-risk populations
  • Establishing public-private partnerships to fund and accelerate dengue vaccine research and distribution
  • Utilizing digital health tools to monitor and manage post-vaccination outcomes for continuous improvement
• Market Challenges
  • Logistical issues in vaccine delivery and vaccine hesitancy

Porter's Five Forces: A Strategic Tool for Navigating the Dengue Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dengue Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dengue Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dengue Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dengue Vaccine Market

A detailed market share analysis in the Dengue Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dengue Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dengue Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dengue Vaccine Market

A strategic analysis of the Dengue Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dengue Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca, Bharat Biotech, Bio Farma, Biological E. Limited, CSL Limited, CureVac AG, GeneOne Life Science, Inc., GlaxoSmithKline plc, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Medigen Vaccine Biologics Corp., Merck & Co., Inc., Panacea Biotec, PaxVax, Inc., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, and Vabiotech.

Market Segmentation & Coverage

This research report categorizes the Dengue Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Vaccine Type, market is studied across DNA Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Subunit Vaccines.
• Based on End User, market is studied across Clinics, Government and Non-Government Organizations, Hospitals, and Research Institutes.
• Based on Age Group, market is studied across Adolescent, Adult, and Pediatric.
• Based on Vaccine Development Stage, market is studied across Clinical Trials, Phase I, Phase II, Phase III, and Pre-Clinical.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Route of Administration, market is studied across Injection, Nasal, and Oral.
• Based on Technology, market is studied across Conventional Vaccines and Next-Generation Vaccines. The Conventional Vaccines is further studied across Split Virus Vaccines and Whole Virus Vaccines. The Next-Generation Vaccines is further studied across Virus-Like Particles.
• Based on Patient Type, market is studied across Symptomatic.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased global incidence of dengue fever cases leading to higher demand for vaccines in affected regions
    • 5.1.1.2. Growing government and non-governmental organizations' initiatives to control and prevent dengue outbreaks
    • 5.1.1.3. Rapid advancements in biotechnology facilitating the development of more effective dengue vaccines
    • 5.1.1.4. Rising public awareness and education campaigns about the importance of dengue vaccination
  • 5.1.2. Restraints
    • 5.1.2.1. High R&D and clinical trial costs

• 5.1.3. Opportunities
  • 5.1.3.1. Developing targeted marketing strategies to increase awareness and adoption of dengue vaccines among at-risk populations
  • 5.1.3.2. Establishing public-private partnerships to fund and accelerate dengue vaccine research and distribution
  • 5.1.3.3. Utilizing digital health tools to monitor and manage post-vaccination outcomes for continuous improvement
• 5.1.4. Challenges
  • 5.1.4.1. Logistical issues in vaccine delivery and vaccine hesitancy

• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dengue Vaccine Market, by Vaccine Type

• 6.1. Introduction
• 6.2. DNA Vaccines
• 6.3. Inactivated Vaccines
• 6.4. Live Attenuated Vaccines
• 6.5. Recombinant Vaccines
• 6.6. Subunit Vaccines

7. Dengue Vaccine Market, by End User

• 7.1. Introduction
• 7.2. Clinics
• 7.3. Government and Non-Government Organizations
• 7.4. Hospitals
• 7.5. Research Institutes

8. Dengue Vaccine Market, by Age Group

• 8.1. Introduction
• 8.2. Adolescent
• 8.3. Adult
• 8.4. Pediatric

9. Dengue Vaccine Market, by Vaccine Development Stage

• 9.1. Introduction
• 9.2. Clinical Trials
• 9.3. Phase I
• 9.4. Phase II
• 9.5. Phase III
• 9.6. Pre-Clinical

10. Dengue Vaccine Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Dengue Vaccine Market, by Route of Administration

• 11.1. Introduction
• 11.2. Injection
• 11.3. Nasal
• 11.4. Oral

12. Dengue Vaccine Market, by Technology

• 12.1. Introduction
• 12.2. Conventional Vaccines
  • 12.2.1. Split Virus Vaccines
  • 12.2.2. Whole Virus Vaccines
• 12.3. Next-Generation Vaccines
  • 12.3.1. Virus-Like Particles

13. Dengue Vaccine Market, by Patient Type

• 13.1. Introduction
• 13.2. Symptomatic

14. Americas Dengue Vaccine Market

• 14.1. Introduction
• 14.2. Argentina
• 14.3. Brazil
• 14.4. Canada
• 14.5. Mexico
• 14.6. United States

15. Asia-Pacific Dengue Vaccine Market

• 15.1. Introduction
• 15.2. Australia
• 15.3. China
• 15.4. India
• 15.5. Indonesia
• 15.6. Japan
• 15.7. Malaysia
• 15.8. Philippines
• 15.9. Singapore
• 15.10. South Korea
• 15.11. Taiwan
• 15.12. Thailand
• 15.13. Vietnam

16. Europe, Middle East & Africa Dengue Vaccine Market

• 16.1. Introduction
• 16.2. Denmark
• 16.3. Egypt
• 16.4. Finland
• 16.5. France
• 16.6. Germany
• 16.7. Israel
• 16.8. Italy
• 16.9. Netherlands
• 16.10. Nigeria
• 16.11. Norway
• 16.12. Poland
• 16.13. Qatar
• 16.14. Russia
• 16.15. Saudi Arabia
• 16.16. South Africa
• 16.17. Spain
• 16.18. Sweden
• 16.19. Switzerland
• 16.20. Turkey
• 16.21. United Arab Emirates
• 16.22. United Kingdom

17. Competitive Landscape

• 17.1. Market Share Analysis, 2023
• 17.2. FPNV Positioning Matrix, 2023
• 17.3. Competitive Scenario Analysis
• 17.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AstraZeneca
• 2. Bharat Biotech
• 3. Bio Farma
• 4. Biological E. Limited
• 5. CSL Limited
• 6. CureVac AG
• 7. GeneOne Life Science, Inc.
• 8. GlaxoSmithKline plc
• 9. Inovio Pharmaceuticals, Inc.
• 10. Johnson & Johnson
• 11. Medigen Vaccine Biologics Corp.
• 12. Merck & Co., Inc.
• 13. Panacea Biotec
• 14. PaxVax, Inc.
• 15. Pfizer Inc.
• 16. Sanofi
• 17. Serum Institute of India Pvt. Ltd.
• 18. Sinovac Biotech Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Vabiotech